NexImmune Inc (NEXI)
3.37
-0.04
(-1.17%)
USD |
NASDAQ |
Apr 26, 16:00
3.42
+0.05
(+1.48%)
After-Hours: 20:00
NexImmune Cash from Operations (TTM): -31.43M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -31.43M |
| September 30, 2023 | -36.72M |
| June 30, 2023 | -41.30M |
| March 31, 2023 | -47.00M |
| December 31, 2022 | -51.19M |
| September 30, 2022 | -51.50M |
| June 30, 2022 | -49.22M |
| Date | Value |
|---|---|
| March 31, 2022 | -51.10M |
| December 31, 2021 | -45.79M |
| September 30, 2021 | -41.54M |
| June 30, 2021 | -38.66M |
| March 31, 2021 | -31.05M |
| December 31, 2020 | -26.40M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-51.50M
Minimum
Sep 2022
-26.40M
Maximum
Dec 2020
-41.76M
Average
-41.54M
Median
Sep 2021
Cash from Operations (TTM) Benchmarks
| Revelation Biosciences Inc | -7.286M |
| Spectral AI Inc | -- |
| Corbus Pharmaceuticals Holdings Inc | -36.10M |
| Processa Pharmaceuticals Inc | -8.063M |
| Ensysce Biosciences Inc | -10.78M |